Analystreport

ProQR Therapeutics NV (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.

ProQR Therapeutics N.V. - Ordinary Shares  (PRQR) 
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: proqr.com